Orally taken medicament formulation of clindamycin phosphate and preparing method thereof

Abstract

The invention discloses a clindamycin phosphate oral pharmaceutical preparation, which is mainly prepared from raw materials in the following weight ratio: (1) a buccal tablet which comprises 1 to 100 portions of clindamycin phosphate counted on clindamycin, 0 to 100 portions of disintegrant, and 5 to 500 portions of filler; (2) a filmogen which comprises 1 to 100 portions of the clindamycin phosphate counted on the clindamycin, and 5 to 500 portions of film-forming material; and (3) an oral patch which comprises 1 to 100 portions of the clindamycin phosphate counted on the clindamycin, 5 to 500 portions of the filler, and 1 to 100 portions of adhesive material. The clindamycin phosphate oral pharmaceutical preparation is directly applied to a local infection and has high local drug concentration and fast effect, and the dose is low and adverse reactions are few.

Description

technical field [0001] The invention relates to a pharmaceutical preparation, in particular to a clindamycin phosphate oral pharmaceutical preparation and a preparation method thereof. Background technique [0002] Clindamycin phosphate, 6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thiomethyl-7(S)-chloro-6,7 , 8-trideoxy-L-threo-α-D-galactopyranoside-2-dihydrogen phosphate, is an antibiotic. Clindamycin phosphate is a derivative of clindamycin. Its mechanism of action is the same as that of clindamycin and lincomycin. It mainly inhibits the elongation of the peptide chain during protein synthesis, thereby affecting the synthesis of bacterial cell proteins. The site is on the 50S subunit of the ribosome. Preclinical pharmacology studies have shown that, as a semi-synthetic clindamycin derivative, clindamycin phosphate has no antibacterial activity in vitro, and after entering the body, it is rapidly hydrolyzed into clindamycin to display its pharmacological acti...

AI Technical Summary

Problems solved by technology

[0004] 1. Systemic medication: The drug is distributed to various tissues of the body, which not only causes many adverse reactions, but also affects the whole body flora, which may cause flora imbalance and cause secondary infection, such as pseudomembranous enteritis

[0005]2. Slow onset: the drug is disintegrated and absorbed through the digestive tract or enters the blood through injection, enters the oral cavity through blood circulation, and takes a long time to reach the effective concentration in the oral cavity. Slow onset

[0007]4. Poor effect on some oral infections: especially for the treatment of pulpitis, the drug can only reach the inflammation site through the small apical foramen, so it is difficult to achieve effective treatment. Therapeutic concentration, causing repeated attacks of toothache